Diabetic macular oedema
In the RESTORE extension study, Prof Paolo Lanzetta from the Department of Ophthalmology, University of Udine introduced results from 240 patients with diabetic macular oedema (DME) who received individualised treatment with ranibizumab in a regimen consistent with the European Union label, the standard of care in wet AMD. The data presented at the 12th EURETINA Congress in Milan, Italy, showed that patients who were originally treated with ranibizumab received an average of 13.9 injections over three years. The mean of seven letters of visual acuity gained in the RESTORE core study were maintained with an average of 3.7 injections in the second year and 2.7 in the third year.Â
Latest Articles
Addressing Postoperative Visual Complications
Managing aberrations after laser refractive surgery requires a multi-layered approach.
3D Printing Helps Transform Ukrainian Eye Care
The country’s ophthalmologists offer valuable experience in treating ocular trauma and prosthesis design.
Winning Essay Says ‘Collective Desire’ Must Drive DEI Implementation
Emerging Microbial Trends That Could Affect Your Practices
A triptych of challenges paints a concerning picture for ophthalmologists across the globe.
Improving Outcomes with Laser-Assisted Surgery
Femtosecond laser offers a multifunctional tool for improving the safety and efficacy of cataract and refractive lens exchange procedures.
Could the Corneal Transplant Pool Increase?
Modifying or discarding major contraindications for keratoplasty could mean more patients have their sight restored.
Matching Premium IOLs to Visual Lifestyles
From monofocal to full-range solutions, each practice needs comprehensive understanding.
Going Dutch on Acanthamoeba Keratitis
A world-first trial suggests a new medication could beat the disease.
Avoiding Intracorneal Ring Segment Complications
Femtosecond lasers are helping improve refractive results with fewer problems.